Using of checkpoint inhibitors as a treatment for melanoma
| dc.contributor.author | Netfa, Khadija | |
| dc.date.accessioned | 2020-07-07T10:08:20Z | |
| dc.date.available | 2020-07-07T10:08:20Z | |
| dc.date.issued | 2020-02-18 | |
| dc.description | Immune checkpoint inhibitors are drugs that help the immune system to release “brakes” of inhibitory receptors expressed on the surface of activated T-cells, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses. Ipilimumab and Nivolumab are examples of immune checkpoint inhibitors, where ipilimumab targets CTLA-4 and nivolumab targets PD1/PD-L1 | en_US |
| dc.description.abstract | Immune checkpoint blockade has used as a treatment of patients with advanced melanoma and many other cancers. Blockade of inhibitory receptors, cytotoxic Tlymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses, based on their studies and mechanism of action in the treatment of metastatic melanoma | en_US |
| dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/1723 | |
| dc.language.iso | en | en_US |
| dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title | Using of checkpoint inhibitors as a treatment for melanoma | en_US |
| dc.type | Other | en_US |